Are lipid mediators implicated in the production of pro- and anti-inflammatory cytokines during cardiopulmonary bypass graft with extracorporeal circulation?

被引:8
作者
Denizot, Y
Feiss, P
Nathan, N
机构
[1] CHRU Dupuytren, Dept Anesthesie Reanimat, F-87042 Limoges, France
[2] Fac Med Limoges, Lab Hematol Expt, F-87025 Limoges, France
关键词
cardiopulmonary bypass; cytokines; inflammation; lipid mediators;
D O I
10.1006/cyto.1998.0428
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study the authors assessed the sequential release of lipid mediators (TXB2, PGE(2), 6-keto-PGF(1 alpha), LTB4, LTC4, PAF), pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and anti-inflammatory cytokines (IL-4, IL-10) in 17 patients undergoing coronary artery bypass graft (CABG) with extracorporeal circulation (ECC). Time course of appearance of inflammatory mediators revealed the early and transient increase in lipid mediator plasma concentrations (6-keto-PGF(1 alpha), LTB4, LTC4, PAF) whereas cytokines (IL-6, IL-8, IL-10) were involved only in late pre- and post-operative periods. No variation of TXB2, PGE(2), IL-4 and TNF-alpha levels were found. No correlation was documented between the levels of lipid mediators and pro- or anti-inflammatory cytokines suggesting that lipidic compounds are not implicated in the genesis of cytokines which appear much later involved. Despite the common use of high doses of aprotinin (a non-specific enzyme inhibitor) in hope to abrogate the inflammatory response to cardiopulmonary bypass procedure, this study reports the persistent release of several inflammatory compounds that might be involved in the post-CABG multiple organ failure syndromes. (C) 1999 Academic Press.
引用
收藏
页码:301 / 304
页数:4
相关论文
共 23 条
[1]  
BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958
[2]  
BONAVIDA B, 1994, CLIN REV ALLERG, V12, P381
[3]   INFLAMMATORY RESPONSE TO CARDIOPULMONARY BYPASS [J].
BUTLER, J ;
ROCKER, GM ;
WESTABY, S .
ANNALS OF THORACIC SURGERY, 1993, 55 (02) :552-559
[4]  
Casey LC, 1993, ANN THORAC SURG, V56, P92
[5]  
CAZENAVE JP, 1979, LAB INVEST, V41, P275
[6]   LEUKOTRIENE-B4 IN THE IMMUNE-SYSTEM [J].
CLAESSON, HE ;
ODLANDER, B ;
JAKOBSSON, PJ .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (03) :441-449
[7]  
Denizot Y, 1997, HANDB EXP PHARM, V126, P483
[8]   Plasma leukaemia inhibitory factor, interleukin 6 and soluble interleukin 6 receptor levels during cardiopulmonary bypass with extracorporeal circulation [J].
Denizot, Y ;
Lorgeot, V ;
Cornu, E ;
Nathan, N .
CYTOKINE, 1998, 10 (04) :303-306
[9]  
FAYMONVILLE ME, 1986, J THORAC CARDIOV SUR, V91, P858
[10]   LEUKOTRIENES IN HEALTH AND DISEASE [J].
FEUERSTEIN, G ;
HALLENBECK, JM .
FASEB JOURNAL, 1987, 1 (03) :186-192